{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:59:20Z","timestamp":1786996760130,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.semarthrit.2018.11.006","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T21:28:12Z","timestamp":1543872492000},"page":"56-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Recapture and improved outcome of pegloticase response with methotrexate\u2013A report of two cases and review of the literature"],"prefix":"10.1016","volume":"49","author":[{"given":"Sarah Y.","family":"Bessen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Y.","family":"Bessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christianne M.","family":"Yung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2018.11.006_bib0001","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","article-title":"Global epidemiology of gout: prevalence, incidence and risk factors","volume":"11","author":"Kuo","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2018.11.006_bib0002","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","article-title":"Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.11.006_bib0003","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ndt\/gfu352","article-title":"Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study","volume":"30","author":"Jing","year":"2015","journal-title":"Nephrol Dial Transpl: Off Publ Eur Dial Transpl Assoc\u2013Eur Renal Assoc"},{"key":"10.1016\/j.semarthrit.2018.11.006_bib0004","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13075-015-0610-9","article-title":"Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies","volume":"17","author":"Roughley","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"4\u20136","key":"10.1016\/j.semarthrit.2018.11.006_bib0005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/15257770.2013.853785","article-title":"Metabolic syndrome in primary gout","volume":"33","author":"Gonzalez-Senac","year":"2014","journal-title":"Nucleosides Nucleotides Nucl Acids"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.11.006_bib0006","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2012-202421","article-title":"Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout","volume":"73","author":"Perez-Ruiz","year":"2014","journal-title":"Ann Rheumat dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2018.11.006_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134088","article-title":"Gout and risk of myocardial infarction: a systematic review and meta-analysis of cohort studies","volume":"10","author":"Liu","year":"2015","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.11.006_bib0008","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/annrheumdis-2014-205252","article-title":"Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink","volume":"74","author":"Clarson","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2018.11.006_bib0009","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.semarthrit.2018.11.006_bib0010","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/ar4318","article-title":"Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy","volume":"15","author":"Baraf","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.11.006_bib0011","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF00163854","article-title":"Two independent mutational events in the loss of urate oxidase during hominoid evolution","volume":"34","author":"Wu","year":"1992","journal-title":"J Mol Evol"},{"issue":"12","key":"10.1016\/j.semarthrit.2018.11.006_bib0012","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.drudis.2014.08.015","article-title":"Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics","volume":"19","author":"Verhoef","year":"2014","journal-title":"Drug Discov Today"},{"issue":"2","key":"10.1016\/j.semarthrit.2018.11.006_bib0013","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.11.006_bib0014","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2018.11.006_bib0015","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"S10","key":"10.1016\/j.semarthrit.2018.11.006_bib0016","first-page":"(S1813)","article-title":"Serum Uric Acid As a Biomarker for Mitigation of Infusion Reactions in Patients Treated with Pegloticase for Refractory Chronic Gout","volume":"66","author":"Baraf","year":"2014","journal-title":"Arthritis and Rheumatology"},{"key":"10.1016\/j.semarthrit.2018.11.006_bib0017","series-title":"KRYSTEXXA [Package insert]","year":"2016"},{"issue":"10","key":"10.1016\/j.semarthrit.2018.11.006_bib0018","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1016\/j.transproceed.2018.03.010","article-title":"A case report of immunosuppressant medication-associated polyarticular tophaceous gout successfully treated using the polyethylene glycol-conjugated uricase enzyme pegloticase","volume":"50","author":"Freyne","year":"2018","journal-title":"Transplant Proc"},{"issue":"6","key":"10.1016\/j.semarthrit.2018.11.006_bib0019","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.semarthrit.2016.09.007","article-title":"Pegloticase failure and a possible solution: immunosuppression to prevent intolerance and inefficacy in patients with gout","volume":"46","author":"Berhanu","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.11.006_bib0020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis","volume":"108","author":"Nanda","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.semarthrit.2018.11.006_bib0021","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"issue":"15","key":"10.1016\/j.semarthrit.2018.11.006_bib0022","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2018.11.006_bib0023","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.11.006_bib0024","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2133\/dmpk.DMPK-13-RV-119","article-title":"Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy","volume":"29","author":"Inoue","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"issue":"12","key":"10.1016\/j.semarthrit.2018.11.006_bib0025","first-page":"2365","article-title":"Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis","volume":"34","author":"Haggerty","year":"2007","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2018.11.006_bib0026","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.cgh.2014.01.033","article-title":"Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy","volume":"12","author":"Baert","year":"2014","journal-title":"Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"2","key":"10.1016\/j.semarthrit.2018.11.006_bib0027","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/rheumatology\/kev277","article-title":"Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice","volume":"55","author":"Schaeverbeke","year":"2016","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.semarthrit.2018.11.006_bib0028","first-page":"549","article-title":"Is methotrexate nephrotoxic? Dose-dependency, comorbidities and comedication","volume":"70","author":"Erdbrugger","year":"2011","journal-title":"Z Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.11.006_bib0029","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10067-015-2861-x","article-title":"Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint?","volume":"34","author":"Witte","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.11.006_bib0030","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/rheumatology\/kei193","article-title":"Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis","volume":"45","author":"Kapetanovic","year":"2006","journal-title":"Rheumatology (Oxford, England)"},{"issue":"7","key":"10.1016\/j.semarthrit.2018.11.006_bib0031","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, anti-tumor necrosis factor alpha, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res"},{"issue":"9","key":"10.1016\/j.semarthrit.2018.11.006_bib0032","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2017-211128","article-title":"Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"76","author":"Park","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"#cr-split#-10.1016\/j.semarthrit.2018.11.006_bib0033.1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - Identifier NCT03303989, REduCing Immunogenicity to PegloticasE (RECIPE) Study"},{"key":"#cr-split#-10.1016\/j.semarthrit.2018.11.006_bib0033.2","unstructured":"2017 October 6 [cited 2018 August 23]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03303989."},{"key":"#cr-split#-10.1016\/j.semarthrit.2018.11.006_bib0034.1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - Identifier NCT02598596, Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect"},{"key":"#cr-split#-10.1016\/j.semarthrit.2018.11.006_bib0034.2","unstructured":"2015 November 6 [cited 2018 August 23]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT02598596."}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901721830547X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901721830547X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T12:44:52Z","timestamp":1564145092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004901721830547X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S004901721830547X"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.11.006","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recapture and improved outcome of pegloticase response with methotrexate\u2013A report of two cases and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}